Lixte Biotechnology HOLDINGS, Inc. (LIXT) intrinsic value & 10-year financials
Lixte Biotechnology HOLDINGS, Inc. (LIXT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -216.4%
- Free cash flow (FY2025)
- —
LIXT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$6.1M | -$1.26 | — | — | -102.2% |
| FY2024 | — | -$3.6M | -$1.59 | — | — | -148.7% |
| FY2023 | — | -$5.1M | -$2.66 | — | — | -111.1% |
| FY2022 | — | -$6.3M | -$3.99 | — | — | -126.8% |
| FY2021 | — | -$6.7M | — | — | — | -137.3% |
| FY2020 | — | -$3.3M | — | — | — | -87.7% |
| FY2019 | — | -$2.4M | — | — | — | -74.4% |
| FY2018 | — | -$2.1M | — | — | — | -83.3% |
| FY2017 | — | -$1.8M | — | — | — | -299.0% |
| FY2016 | — | -$2.1M | — | — | — | -994.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. has historically struggled to out-earn its cost of capital, averaging just -88.4% ROIC.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
LIXTE BIOTECHNOLOGY HOLDINGS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.